Arrowhead Pharmaceuticals, Inc. (ARWR)

Market Cap	3.13B
Revenue (ttm)	256.21M
Net Income (ttm)	-181.11M
Shares Out	107.19M
EPS (ttm)	-1.71
PE Ratio	n/a
Forward PE	111.11
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,072
Open	29.48
Previous Close	28.92
Day's Range	27.92 - 29.10
52-Week Range	22.87 - 42.48
Beta	0.88
Analysts	Buy
Price Target	55.60 (+92.25%)
Earnings Date	Nov 29, 2023

About ARWR

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clin...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 16, 1993
• Employees: 397
• Stock Exchange: NASDAQ
• Ticker Symbol: ARWR

Financial Performance

In 2022, ARWR's revenue was $243.23 million, an increase of 75.89% compared to the previous year's $138.29 million. Losses were -$176.06 million, 25.0% more than in 2021.

Analyst Forecast

According to 16 analysts, the average rating for ARWR stock is "Buy." The 12-month stock price forecast is $55.6, which is an increase of 92.25% from the latest price.

Price Target

$55.6

(92.25% upside)

Analyst Consensus: Buy